No. A US pharmacy still cannot lawfully compound BPC-157, and it is not an approved drug. In 2026 FDA took it off a safety-risk list and an advisory committee voted to recommend it, but neither step is permission.
The sentence to unlearn first
"BPC-157 is legal now."
It is the single most common thing a reader believes in August 2026, it comes from real events reported accurately, and it is wrong. Understanding why takes about five minutes and it changes what you think you are buying.
What actually happened, in order
April 2026. FDA removed twelve peptides from Category 2, its list of bulk drug substances that "may present significant safety risks" when used in compounding. Among them: BPC-157, TB-500, MOTS-c, Epitalon, injectable GHK-Cu, cathelicidin LL-37, Melanotan II, dihexa and PEG-MGF. Most came off because the person or company who nominated them for evaluation withdrew the nomination, not because FDA concluded they were safe.
July 2026. A two-day meeting of the Pharmacy Compounding Advisory Committee voted on seven peptides. BPC-157 was recommended 8–6–1. TB-500 8–6–1. MOTS-c 7–5–2. Epitalon 7–5–1. Semax 8–5–1. KPV 8–6–1. DSIP was voted down, 6–7–1, the only rejection.
Two details are worth more than the vote counts. FDA's own multidisciplinary review team recommended against all seven. And the committee is advisory: its votes are recommendations to the agency, not decisions.
Why none of that is permission
A compounding pharmacy operating under section 503A may only use a bulk drug substance if one of three things is true. The substance has a USP or NF monograph. Or it is a component of an FDA-approved drug. Or it appears on the 503A bulks list.
Coming off Category 2 achieves none of the three. It removes a warning label from a list; it does not add the substance to a different list. Getting onto the 503A bulks list requires rulemaking, a formal, published, comment-driven process. As of 27 September 2026 it has not started for any of these compounds, and FDA has not given a date.
So the honest status of BPC-157 on 3 August 2026 is: recommended by an advisory committee, against the advice of FDA's own scientists, for a rule that does not exist yet. Not lawfully compoundable.
The part nobody mentions: what FDA was actually assessing
Read the indications the committee voted on, next to what people actually use these compounds for.
| Compound | Indication FDA assessed |
|---|---|
| BPC-157 | Ulcerative colitis |
| TB-500 | Wound healing |
| MOTS-c | Obesity and osteoporosis |
| Epitalon | Insomnia |
| Semax | Cerebral ischaemia, migraine, trigeminal neuralgia |
| KPV | Wound healing and inflammatory conditions |
Almost nobody in the community uses them for those things. The tendon-repair use of BPC-157, the anti-ageing use of Epitalon, the cognitive-enhancement use of Semax. None of those were assessed by anyone. Whatever eventually comes out of rulemaking will be scoped to the indication that was voted on. A rule permitting BPC-157 for ulcerative colitis does not make a compounded vial for a sore Achilles lawful.
Two more things that are true and get conflated
Removal from Category 2 is not the same as removal from Category 1. Category 1 substances were under enforcement discretion. FDA was choosing not to act. Topical GHK-Cu was removed from Category 1 in April 2026 and lost that discretion. The route with the best human evidence in that compound's file ended up in a worse position, on the same day the injectable route came off the safety-risk list.
FDA reclassification has no effect whatsoever on anti-doping status. BPC-157 remains prohibited under WADA's S0 catch-all regardless of what any bulks list says. The two systems are unrelated, and anti-doping enforcement is non-analytical: an athlete can be sanctioned on admissions, possession or records, without a positive test.
What to do with this
When you read that something is "now legal", ask which list it moved on or off, who moved it, whether rulemaking has happened, and for which indication. Four questions. They will resolve almost every regulatory claim you meet, and the answer is usually "less than the headline said".